Abstract
Lung cancer is one of the most prevalent cancers in men and women and has the highest mortality rate of all cancers except non-melanoma skin cancer. Approximately 85% of the cases are non-small cell lung cancer (NSCLC) and, among these, about 3% present the ALK+ translocation. The aim of this analysis is to compare costs between lorlatinib and alectinib in the ALK+ NSCLC in first line treatment from the Brazilian private healthcare system perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have